Furthermore, they confirmed that blocking the IL-6 receptor or Notch3 inhibition may be superior to STAT-3 inhibition for CSC-targeting therapies concomitant with anticancer drugs in CRC cell lines (66). The gene discussed is STAT3; the disease is colorectal carcinoma.